METHYL FORMATE
Organic Service Branch II 1. General Discussion
This evaluation was undertaken to develop a sampling and analytical procedure for methyl formate at the OSHA PEL 100 ppm (Ref. 5.1.). 1.1.2. Toxic effects (This section is for information only and should not be taken as the basis of OSHA policy.) Inhalation of vapor produces nasal and conjunctival irritation, retching, narcosis, and death from pulmonary effects (Ref. 5.2., 5.3. and 5.4.). 1.1.3. Potential workplace exposure Methyl formate has been employed as a fumigant and larvicide, as well as a solvent for cellulose acetate and in organic synthesis. (Ref. 5.2., 5.3. and 5.4.). No data is available on the extent of work place exposure. 1.1.4. Physical properties (Ref. 5.2., 5.3. and 5.4.)
1.2. Limit defining parameters The detection limit of the analytical procedure, including a 2.7:1 split ratio, is 3.16 ng per injection. This is the amount of analyte which will give a peak whose height is approximately five times the baseline noise. 2. Sampling Procedure
2.1.2. A sample is collected with 2.2. Reagents No sampling reagents are required. 2.3. Sampling technique
2.3.2. Attach the sampling tube to the sampling pump with
flexible tubing. Position the tube so that sampled air first passes
through the 2.3.3. Attach the tube vertically in the employee's breathing zone in such a manner that it does not impede work performance. 2.3.4. After sampling for the appropriate time, remove the sample tube and seal it with plastic caps. 2.3.5. Wrap each sample 2.3.6. Record the air volume for each sample and list any possible interferences. 2.3.7. Submit at least one blank for each set of samples. Handle the blank in the same manner as the samples, except no air is drawn through it. 2.3.8. Ship the samples cold after sampling to the laboratory and analyzed immediately. 2.3.9. Submit bulk samples for analysis in a separate container. Do not ship bulk samples with air samples. 2.4. Desorption efficiency Twelve vials, each containing
Desorption Efficiency
2.5. Retention efficiency Four Anasorb 747 tubes were each liquid spiked with 1.6 µL (1× PEL) of 50% methyl formate in methyl alcohol. These were allowed to equilibrate for 2 hours and then 3 L of humid air (~80% relative humidity) were drawn through each tube at 0.05 L/min. Then the tubes were desorbed with 3.0 mL of desorbing solution, and then analyzed as in Section 3. The results are listed in Table 2.5.
Retention Efficiency
2.6. Sample storage Nine Anasorb 747 tubes were each liquid spiked with 1.6 µL (1× PEL) of 50% methyl formate in methyl alcohol. These were allowed to equilibrate for 2 hours and then 3 L of humid air (~80% relative humidity) were drawn through each tube at 0.05 L/min. The nine tubes were divided into three groups of three tubes each. The first group was stored in a drawer at ambient temperature, the second group was stored in a refrigerator (0°C) and the third group was stored in a freezer (-5°C). After seven days they were extracted and analyzed as in Section 3. No analytes were observed in backup section. The results are given in Tables 2.6.1., 2.6.2. and 2.6.3..
Ambient Storage
Refrigerator Storage
Freezer Storage
2.7. Recommended air volume and sampling rate
2.7.2. The recommended flow rate is 0.05 L/min. 2.8. Interferences (sampling) It is not known if any compounds will interfere with the collection of methyl formate. Any suspected interferences should be reported to the laboratory with submitted samples. 2.9. Safety precautions (sampling)
2.9.2. Follow all safety practices that apply to the work area being sampled. 3. Analytical Procedure
3.1.2. A GC column capable of separating methyl formate from any interferences. A 60 m × 0.32 mm i.d. (1.0 µm film) STABILWAX capillary column was used in this evaluation. 3.1.3. An electronic integrator or some other suitable means to measure detector response. A Waters 860 Networking Computer System was used in this evaluation. 3.1.4. Volumetric flasks, pipets, and syringes for preparing standards, making dilutions and performing injections. 3.1.5. Vials, 3.1.6. Mechanical shaker. 3.2. Reagents
3.2.2. Methyl alcohol. The methyl alcohol used in this evaluation was purchased from Fisher Scientific. 3.2.3. Dimethylformamide (DMF). The DMF was purchased from Burdick and Jackson. 3.2.4. Desorbing solution, 90/10 (v/v) methyl alcohol and DMF. 3.3. Standard preparation Prepare standards at concentrations of 1 µL, 2 µL and 4 µL of methyl formate per milliliter of desorbing solution. Standards must be used the day they are prepared. 3.4. Sample preparation
3.4.2. Add 3.0 mL of desorbing solultion to each vial and seal
with a 3.4.3. Shake the vials on a mechanical shaker for an hour. 3.5. Analysis
3.5.2. Chromatogram (Figure 1.) 3.5.3. Measure detector response using a suitable method such as electronic integration. 3.6. Interferences (analytical)
3.6.2. GC conditions may generally be varied to circumvent interferences. 3.6.3. Retention time on a single column is not proof of chemical identity. Analysis by an alternate GC column, high performance liquid chromatography (HPLC) and confirmation by mass spectrometry are additional means of identification. 3.7. Calculations
3.7.2. Determine the µg/mL of methyl formate in both sections of each sample and blank from the calibration curve. If methyl formate is found on the backup section, it is added to the amount found on the front section. Blank corrections should be performed before adding the results together. 3.7.3. Determine the air concentration by using the following formula.
3.8. Safety precautions (analytical)
3.8.2. Avoid skin contact with all solvents. 3.8.3. Wear safety glasses in laboratory. 4. Recommendation for Further Study This method should be fully validated.
5.2. Documentation of the Threshold Limit Values and Biological Exposure Indices, American Conference of Governmental Industrial Hygienist INC., 5th ed., 1986; p 397. 5.3. Sitting, M., Handbook of Toxic and Hazardous Chemicals, Noyes Publications, Park Ridge, N.J., 1981; p 453. 5.4. Windholz, M., Budavari, S., Blumetti, RF., and Otterbein, E., The Merck Index, 10th ed., Merck & CO., Inc., Rahway, N.J., 1983; p 870.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||